Bempedoic acid-based therapy
Bempedoic acid-based therapy has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Oct 26, 2026: “Predicted change in 10-year cardiovascular risk one year after initiation of bempedoic acid-based therapy in the MILOS study”.
1 paper studies it2 findingsUpdated
1 new paper in 30 daysSee all 1
“Mean LDL-C reduction from pre-treatment to 1-year follow-up was 0.88 mmol/L”
- 1 lab in 1 country
- 1 of 1 finding with company ties
- Humans1
What is Bempedoic acid-based therapy linked with?
2Studies link Bempedoic acid-based therapy with 2 measures, most often predicted 10-year cardiovascular risk (1 study) and LDL cholesterol (1).
Predicted 10-year cardiovascular risk
downin silico1
1 study
Predicted 10-year cardiovascular risk
downin silico1
Bempedoic acid-based therapy is associated with predicted 10-year cardiovascular risk in silico (Modeled translation of observed LDL-C reductions, assuming sustained LDL-C lowering) (Estimated absolute risk reduction 4.8% (SD 6.7); relative risk reduction 17.1% (SD 20.5)).
“an estimated ARR of 4.8% in 10-year CV risk (SD 6.7; Figure) or a RRR of 17.1% (SD 20.5)”
In silicoModeled translation of observed LDL-C reductions, assuming sustained LDL-C lowering10-year prediction based on 1-year LDL-C changesn = 960
ESC Congress 2026 abstract
LDL cholesterol
downin humans1
1 study
LDL cholesterol
downin humans1
Bempedoic acid-based therapy is associated with LDL cholesterol in humans (−0.88 mmol/L from pretreatment to 1 year).
“Mean LDL-C reduction from pre-treatment to 1-year follow-up was 0.88 mmol/L”
HumansPrimary hypercholesterolemia or mixed dyslipidemia; bempedoic acid alone or in fixed-dose combination with ezetimibe1 yearn = 960
ESC Congress 2026 abstract